Oncology patent intelligence

WO 2026109729

COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN

ASTRAZENECA AB [SE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

WO 2026078615

ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

PFIZER [US] · Granted Thu Apr 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

WO 2026078619

ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

PFIZER [US] · Granted Thu Apr 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12336990

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12144809

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12097198

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11963958

RET inhibitor for use in treating cancer having a RET alteration

Rigel Pharmaceuticals, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11944627

Methods for treating hematological malignancies and Ewing's sarcoma

Kura Oncology, Inc. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11591579

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11583526

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3217490

MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION

AB SCIENCE [FR] · Granted Thu Nov 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11396647

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10953003

Methods for treating cancer

X4 Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10933076

Crocin-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10786501

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10568873

Safranal-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10449191

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 2016175302

MASITINIB FOR TREATING GASTRIC CANCER

AB SCIENCE [FR] · Granted Thu Jun 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

WO 2016096933

MASITINIB COMBINÉ À UTILISER DANS LE TRAITEMENT DU CANCER DU SEIN

AB SCIENCE [FR] · Granted Thu Jun 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 2016128999

MASITINIB FOR TREATING HEPATIC CANCER

AB SCIENCE [FR] · Granted Thu May 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8802689

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

The Regents of the University of California · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8445507

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

The Regents of the University of California · Granted Tue May 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8288342

Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate

TEVA WOMEN'S HEALTH, INC. · Granted Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)